The importance of prognostic factors in premenopausal women with breast cancer

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1893-1896

  Finek, Jindrich ^a,c   Holubec Jr , L ^a   Topolcan, O ^a   Elgrova, L ^a   Skalova, A ^a   Pecen, L ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Premenopausal women; Prognostic factors

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT MONITORING; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; BREAST NEOPLASMS; CA-15-3 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 34250697433     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Goldhirsch A, Glick JH and Gerber RD: Meeting Highlights: International Expert Concensus on the Primary, Therapy of Early Breast Cancer 2005. Ann Oncol 16(10): 1569-1583, 2005.
2. Goldhirsch A, Wood WC and Gerber RD: Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. J Clin Oncol 21: 3357-3365, 2003.
3. Foulkes WD, Brunet JS and Stefansson IM: The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid microvascular- proliferation) phenotype of BRCA1-related breast cancer. Cancer Res 64: 830-835, 2004.
4. Hayes DF: Prognostic and predictive factors revisited. Breast 14(6): 493-499, 2005.
5. Naume B, Wiedswang G and Borgen E: The prognostic value of isolated tumor cells in bone marrow in breast cancer patiens: evaluation of morphologic categories and the number of clinically significant cells. Clin Cancer Res 10: 3091-3097, 2004.
6. Norberg T, Klaar S and Karf G: Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort. Cancer Res 61: 8317-8321, 2001.
7. Sotiriou C, Neo SY and McShane LM: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003.
8. Howell A, Cuzick J, Baum M et al: Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62, 2005.
9. International Breast Cancer Study Group (IBCSG), on behalf of the Breast International Group (BIG): Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomised double-blind phase III study. The Primary Therapy of Early Breast Cancer 9th International Conference in St. Gallen, Switzerland, 26 January 2005.
10. Chang AE and Skibber JM: Evidence-based management of breast cancer. In: Oncology. An Evidence-based Approach. Springer, USA, pp. 951-982, 2006.
11. Bofin AM, Ytterhus B and Martin C: Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 122: 110-119, 2004.
12. Ross JS, Fletcher JA and Linette GP: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8(4): 307-325, 2003.
13. Pinder SE, Ellis IO and Galea M: Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24: 41-47, 1994.
14. Kato T, Kameoa S and Kimura T: The combination of angiogenesis and blood vesel invasion as a prognostic indicator in primary breast cancer. Br J Cancer 88: 1900-1908, 2003.
15. Schoppmann SF, Bayer G and Aumayr K: Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 240: 306-312, 2004.
16. Martin M: Molecular biology of breast cancer. Clin Transl Oncol 8(1): 7-14, 2006.
17. Kroger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR and Loning T: Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 12(1): 159-68, 2006.
18. Fehm T, Becker S, Pergola-Becker G, Kramer B, Gruber I, Sotlar K, Kurek R, Wallwiener D and Solomayer E: Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Res 24(6): 4211-4216.
19. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K and Gerber B: Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 25(3A): 1719-1723, 2005.
20. Becker S, Becker-Pergola G, Fehm T, Wallwiener D and Solomayer EF: Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients. Anticancer Res 25(3B): 2171-2175, 2005.
21. Lumachi F, Basso SM, Brandes AA, Pagano D and Ermani M: Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res 24(5B): 3221-3224, 2004.
22. Jalava P, Kuopio T, Huovinen R, Laine J and Collan Y: Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res 25(3C): 2535-2542, 2005.